Related by context. All words. (Click for frequent words.) 71 Kevetrin ™ 64 Kevetrin TM 63 ASONEP 63 EndoTAG TM -1 63 Onconase 62 HuMax CD# 62 OXi# 62 preclinical efficacy 62 huC# DM4 62 OncoVEX GM CSF 62 cancer immunotherapies 62 nanoviricides 62 Preclinical studies 62 Guanilib 61 UPLYSO 61 MEK inhibitor 61 MVA BN R 61 ANAVEX #-# [001] 61 PD LID 61 proteasome inhibitor 61 tafamidis 61 MEK inhibitors 61 Anticalin R 61 Xanafide 61 Anticalin ® 61 RhuDex ® 61 orally bioavailable 61 receptor inhibitor 61 JAK inhibitor 61 alvespimycin 61 GAP #B# 61 Diamyd ® 61 ospemifene 60 BNC# 60 Cethromycin 60 entinostat 60 isoform selective 60 CGEN # 60 proteasome inhibitors 60 liposomal formulation 60 preclinically 60 Aplidin 60 Ceflatonin 60 anti CD3 60 targeting CD# 60 Bezielle 60 tipifarnib 60 Preclinical studies suggest 60 XmAb# 60 HuMax CD4 60 TRIOLEX 60 RAV# 60 talabostat 60 Kahalalide F 60 YONDELIS 60 Archexin 60 HSP# inhibitor 60 GRNVAC1 60 Synavive 60 IMA# 60 preclinical 60 AKT inhibitor 59 immunotherapeutic 59 EOquin TM 59 EGS# 59 Anticalin 59 RhuDex R 59 Mipomersen 59 PDE4 inhibitor 59 bortezomib Velcade 59 DXL# 59 HuMax EGFr 59 DB# [003] 59 ENMD # 59 aurora kinase 59 Phase Ib clinical 59 iSONEP 59 vascular disrupting agent 59 CDK inhibitor 59 antibody MAb 59 BRAF inhibitor 59 Abiraterone acetate 59 Sym# 59 HGS# 59 Azedra 59 ganetespib 59 Tyrima 59 Serdaxin 59 immunotoxin 59 GLP toxicology studies 59 ImmunoVEX HSV2 59 NEUGENE 59 PLK1 SNALP 59 Bortezomib 59 IMGN# 59 zileuton 59 PSMA ADC 59 RGB # 59 Cytolin R 59 ONCONASE R 59 JAK inhibitors 59 Thiarabine 59 ONCONASE 59 KRN# 59 Prodarsan ® 59 histone deacetylase inhibitor 59 AAG geldanamycin analog 59 preclinical toxicology 59 enzastaurin 59 Aflibercept 59 rxRNA 59 receptor tyrosine kinase inhibitor 59 SGS# 59 antisense drug 59 siRNA therapeutics 58 CCX# 58 DermaVir Patch 58 R#/MEM # 58 huN# DM1 58 Tanespimycin 58 angiogenesis inhibitor 58 TREANDA 58 vascular disrupting agents 58 AP# [003] 58 vidofludimus 58 NexACT 58 ATL# [001] 58 Curaxin 58 Symadex 58 CYT# potent vascular disrupting 58 OHR/AVR# 58 phase IIb clinical 58 Urocidin 58 CBLC# 58 SNT MC# 58 deforolimus 58 Curaxin CBLC# 58 systemically administered 58 Pimavanserin 58 Azixa 58 AQ4N 58 HuLuc# 58 Anavex #-# 58 pradefovir 58 Valortim 58 atacicept 58 tiapamil 58 Phase IIa proof 58 Panzem 58 Pradefovir 58 ARIKACE ™ 58 Sphingomab 58 Posiphen 58 anti CD3 monoclonal 58 humanized anti 58 acyclovir Lauriad R 58 BiTE 58 Hsp# inhibition 58 OncoVEX 58 favorable pharmacokinetic profile 58 Virulizin 58 OMP #M# 58 Genz # 58 obatoclax 58 vivo validation 58 demonstrated antitumor activity 58 personalized immunotherapy 58 PXD# 58 Lenocta 58 nonclinical studies 58 Orazol 58 Aurora kinase inhibitor 58 PEG SN# 58 tanespimycin 58 GRN#L 58 PLX# 58 Spiegelmer ® 58 lumiliximab 58 NGX# 58 Safinamide 58 Zybrestat 58 siRNA therapeutic 58 IIa trial 58 humanized antibody 58 non nucleoside HCV 58 LY# [002] 58 HGS ETR1 57 Panzem R 57 novel anticancer 57 Perifosine 57 MT# MEDI 57 ATL# [002] 57 axitinib 57 iroxanadine 57 orally dosed 57 targeted radiotherapeutic 57 PI3K/Akt pathway inhibitor 57 ocular formulation 57 ELND# 57 tubulin inhibitor 57 LY# [003] 57 Angiocept 57 PCK# 57 thymalfasin 57 ANAVEX #-# [003] 57 polymerase inhibitor 57 humanized monoclonal antibodies 57 orally administered inhibitor 57 MORAb 57 LB# [003] 57 Traficet EN 57 vivo efficacy 57 INCB# [001] 57 vaccines oncolytic virus 57 Multimeric 57 Phase Ib study 57 preclinical studies 57 PKC# 57 lorvotuzumab mertansine 57 EndoTAG TM 57 Anthim 57 crofelemer 57 Virulizin ® 57 masitinib 57 xenograft models 57 Thiovir 57 methylnaltrexone 57 bafetinib 57 anti CD3 antibody 57 phase IIa clinical 57 Phase Ib clinical trials 57 Zolinza 57 novel VDA molecule 57 PI3K inhibitor 57 TKM ApoB 57 PrevOnco 57 CCR2 57 potent anticancer 57 vitro experiments 57 CA4P 57 dexpramipexole 57 BZL# 57 TLR agonists 57 IAP inhibitor 57 otelixizumab 57 FLT3 57 cMET 57 induce apoptosis 57 Tamibarotene 57 Phase 2a clinical trials 57 Phase Ib 57 Phase IIb clinical trials 57 FluCide 57 Atrasentan 57 oral Hsp# inhibitor 57 p# inhibitor 57 nanoviricide 57 retapamulin 57 Iloperidone 57 HDAC inhibitors 57 intranasal formulation 57 PrevOnco ™ 57 potently inhibit 57 anticancer compound 57 #D#C# 57 rBChE 57 HCV protease inhibitors 57 OvaRex R 57 Lpathomab 57 reslizumab 57 tolevamer 57 incyclinide 57 immatics 57 hematological cancers 57 epigenetic therapies 57 bardoxolone 57 NXL# 57 volociximab 57 HCV replicon 57 CCR5 antagonist 57 LPA1 receptor 57 protein kinase inhibitor 57 generation antisense inhibitor 57 Tarvacin Anti Viral 57 Phase #/#a trial 57 SPC# [001] 57 XL# [003] 56 geldanamycin 56 Onalta ™ 56 HCV protease inhibitor 56 CORT # 56 PF # [001] 56 pertuzumab 56 elotuzumab 56 Neugene 56 eniluracil 56 Hsp# inhibitor 56 Ixabepilone 56 sorafenib Nexavar 56 investigational humanized monoclonal antibody 56 Sphingomab TM 56 TOCOSOL Paclitaxel 56 paclitaxel Taxol 56 TLR9 agonists 56 LT NS# 56 trastuzumab DM1 T DM1 56 Neuvenge 56 radiation sensitizer 56 MMP inhibitors 56 Phase IIb trials 56 Lucanix 56 Gleevec resistant 56 splice variants 56 Relivar 56 tramiprosate 56 NP2 Enkephalin 56 depsipeptide 56 tyrosine kinase inhibitor 56 Fc fusion protein 56 PEGPH# 56 exon skipping 56 Gleevec imatinib mesylate 56 JAK1 56 selective immunoproteasome inhibitor 56 Exelixis compounds 56 indibulin 56 JAK2 inhibitor 56 synthetic retinoid 56 humanized monoclonal antibody 56 anti fibrotic 56 oral prodrug 56 transgenic mouse models 56 YONDELIS R 56 potent inhibitor 56 immune modulating 56 MEK inhibitor RDEA# 56 anti angiogenic therapy 56 Phenserine 56 cannabinor 56 INT# [002] 56 enzyme inhibitor 56 SUVN 56 registrational trial 56 fosbretabulin 56 Hedgehog inhibitor 56 Omacetaxine 56 tremelimumab 56 Tarvacin 56 APOPTONE 56 EOquin 56 Vaxfectin 56 RNA antagonists 56 alagebrium 56 Diamyd R 56 HIV integrase inhibitor 56 Phase 2a trial 56 IMC #B 56 ToGA 56 oncolytic virus 56 PS# [001] 56 potent antitumor activity 56 octreotide implant 56 GeneICE 56 JAK3 inhibitor 56 Antisense 56 BiTE antibody 56 Angiolix 56 CG# [003] 56 Atiprimod 56 bendamustine 56 OXIGON TM 56 Enkephalin 56 mAb 56 Vandetanib 56 Cloretazine ® 56 ProSavin 56 MAGE A3 ASCI 56 KNS # 56 MDV# 56 Tarceva TM 56 Virulizin R 56 miglustat 56 mertansine 56 BAL# [002] 56 Anticalins ® 56 phase IIa 56 therapeutic monoclonal antibody 56 Talabostat 56 trodusquemine 56 trastuzumab DM1 56 RNAi therapeutic targeting 56 imatinib Gleevec ® 56 molecularly targeted 56 JP-#/fipamezole 56 generation FBPase inhibitor 56 Irinotecan 56 multi kinase inhibitor 56 poly ADP ribose polymerase 56 trabectedin 56 Seliciclib 56 vivo preclinical 56 therapeutic monoclonal antibodies 56 Squalamine 56 Civacir 56 Carfilzomib 56 TLR8 56 radezolid 56 Ophena TM 56 IND submission 56 pomalidomide 56 gallium containing 56 amrubicin 56 HCV protease 56 immunomodulator 56 MYDICAR ® 56 GLPG# 56 Janus kinase 56 RhuDex 56 phosphatidylserine PS targeting 56 crizotinib PF # 56 GeoVax vaccine 56 anti amnesic 56 Onalta 56 mitogen activated ERK kinase 56 anticancer activity 56 Daclizumab 56 TLR9 agonist 56 gefitinib Iressa 56 CD# antibody [001] 56 compound AEZS 56 investigational compounds 56 Icatibant 56 BMN 56 DermaVir 56 viral kinetics 56 signal transduction inhibitor 56 Pharmacokinetic studies 56 dacetuzumab 56 cediranib 56 inhibited tumor 56 ADAGIO study 56 Belinostat 56 TELINTRA 56 Cerashield 56 anticancer agent 56 calcitonin 56 PRT# 56 humanized antibodies 56 vinca alkaloid 55 AEG# 55 Interferon alpha 55 ASA# 55 Aurora kinase 55 Phase 2a 55 multiple myeloma MM 55 oxidative stress inducer 55 ixabepilone 55 PEG Interferon lambda 55 T#I [002] 55 MAb 55 prostone 55 somatostatin analogue 55 CD3 monoclonal antibody 55 MET amplification 55 nitric oxide donating prostaglandin 55 fipamezole 55 BAY #-# 55 investigational protease inhibitor 55 generation purine nucleoside 55 PNT# 55 BEMA TM Fentanyl 55 chimeric monoclonal antibody 55 ADI PEG 55 ELACYT 55 olaparib 55 OncoVex 55 RhuDex TM 55 class mGluR5 inhibitor 55 KineMed 55 antiangiogenic agent 55 imetelstat 55 Phase #b/#a trial 55 Nanobodies 55 ZFP Therapeutic 55 PSN# [002] 55 rNAPc2 55 SRT# [003] 55 inhibit metastasis 55 beta 1a 55 PRLX # 55 anti angiogenic agent 55 Sudhir Agrawal D.Phil 55 Catena ® 55 ataluren 55 selective modulator 55 Laquinimod 55 cathepsin K inhibitor 55 IL #E 55 mTOR inhibition 55 histone deacetylase HDAC inhibitor 55 polymerase inhibitors 55 Oral NKTR 55 pharmacokinetic PK study 55 TACI Ig 55 Quinamed 55 Olaparib 55 phase IIb study 55 brostallicin 55 Menerba 55 S/GSK# 55 OxBC 55 Triapine R 55 LEX System 55 CCR9 antagonist 55 antisense oligonucleotide 55 T DM1 55 oral antiviral 55 Vectibix panitumumab 55 antitumor 55 CD# CEA 55 TG# [003] 55 immunomodulatory 55 daclizumab 55 Nanobody 55 decitabine 55 mGluR5 negative 55 telomerase therapeutic 55 Hsp# inhibitors 55 trastuzumab emtansine T DM1 55 IPL# 55 TransVax tm 55 generation nucleoside analog 55 ulimorelin 55 oral ridaforolimus 55 pan HDAC inhibitor 55 SAR# [004] 55 Proellex TM 55 Radilex 55 talactoferrin 55 oral PTH 55 investigational compound 55 Targeted Chemotherapy 55 tezampanel NGX# 55 Nuvion 55 cilengitide 55 non nucleoside inhibitor 55 tamibarotene 55 acetonide FA 55 Miraxion 55 Lucanix R 55 PLX cells 55 PI3K/mTOR 55 predictive biomarkers 55 TRC# 55 Nanobodies ® 55 small molecule tyrosine 55 omacetaxine mepesuccinate 55 VEGF inhibitors 55 ICA # 55 A3 adenosine receptor 55 neratinib 55 ALN TTR 55 Cloretazine R 55 regorafenib 55 DFMO 55 Lu AA# 55 MAP# 55 antisense inhibition 55 CIMZIA ™ 55 RNA antagonist 55 temsirolimus 55 HGS ETR2 55 evaluating tivozanib 55 AVE# 55 Hedgehog pathway inhibitor 55 nanoviricide drug 55 MAbs 55 GLYX 55 anidulafungin 55 solithromycin 55 Temsirolimus 55 BCR ABL inhibitor 55 vosaroxin 55 inecalcitol 55 selective kinase inhibitor 55 anticancer therapies 55 oral rivaroxaban 55 chemopreventive agent 55 Ceflatonin R 55 Dextofisopam 55 maximally tolerated dose 55 Tarvacin TM 55 Solorel TM 55 CR# vcMMAE 55 Phase IIa trials 55 CYT# 55 DCCR 55 R roscovitine 55 XL# XL# 55 nucleotide analog 55 ZOLINZA 55 ISIS # 55 bispecific antibody 55 Liprostin 55 BCR ABL inhibitors 55 THR beta agonist 55 prucalopride 55 Phase #b/#a clinical 55 EVIZON TM 55 Panzem R NCD 55 Allovectin 7 55 mGluR2 NAM 55 Panzem NCD 55 antisense drugs 55 Epratuzumab 55 cleavable linker 55 fluoropyrimidine 55 ATL/TV# 55 kinase inhibitor 55 Lisofylline LSF 55 metaglidasen 55 CYT# QbG# 55 IAP inhibitors 55 Phase IIB 55 PF # [002] 55 glucokinase activator 55 XL# anticancer compounds 55 INNO 55 Troxatyl 55 CTAP# Capsules 55 epratuzumab 55 humanized monoclonal 55 Fentanyl TAIFUN R 55 ALN VSP 55 Prestara 55 allosteric modulator NAM 54 Valortim ® 54 Aurograb 54 Telintra 54 Chrysalin 54 selective androgen receptor modulator 54 mda 7 54 seliciclib 54 midstage trials 54 GSK # 54 novel orally bioavailable 54 Xelox 54 Actilon 54 antitumor effects 54 Clevudine 54 Azacitidine 54 tumor antigen 54 seliciclib CYC# 54 induced tumor regression 54 Imprime PGG 54 teplizumab 54 TRX1 54 MGCD# [001] 54 DepoVax ™ 54 GV# [001] 54 ESBA# 54 potently inhibited 54 pharmacodynamic PD 54 rFVIIIFc 54 ZACTIMA 54 erlotinib Tarceva ® 54 pediatric acute lymphoblastic 54 TRV# [001] 54 trastuzumab Herceptin R 54 Interferon beta 54 investigational HCV polymerase 54 DEB# 54 Revimmune 54 nicotinic alpha 7 54 AMPK activators 54 aldehyde dehydrogenase ALDH2 deficiency 54 Firdapse 54 DAVANAT 54 IFN alpha 54 Elvitegravir 54 multikinase inhibitor 54 Velcade bortezomib 54 multitargeted 54 Solazed 54 Oglemilast 54 VA# [002] 54 TRO# 54 danoprevir 54 Phase 1b clinical 54 MGd 54 CCR9 54 laquinimod 54 vemurafenib 54 maturation inhibitor 54 investigational monoclonal antibody 54 XOMA 3AB 54 adecatumumab MT# 54 bexarotene 54 GVAX ® 54 ZD# [001] 54 Phase Ib II 54 Maribavir 54 nucleoside analogues 54 HER2 positive metastatic breast 54 VEGF receptor 54 humanised antibody 54 Pertuzumab 54 ruxolitinib 54 CUDC 54 Pemetrexed 54 Neulasta ® 54 non nucleoside 54 K ras mutations 54 immune modulatory 54 neuroprotective properties 54 PROCHYMAL 54 optimal dosing regimens 54 TKM PLK1 54 Rasagiline 54 eprotirome 54 #ME# 54 HCD# [002] 54 ADVEXIN 54 nab paclitaxel 54 HDL Selective Delipidation 54 INGN 54 Fludara ® 54 immune stimulatory 54 Zalbin 54 immunotherapeutic vaccine 54 tezampanel 54 Aurexis 54 triphendiol 54 maribavir 54 Amrubicin 54 Scancell 54 inhibit tumor 54 Proxinium TM 54 glycosylation profile 54 inhaled AAT 54 Nexavar ® 54 GW# [003] 54 QLT# 54 davunetide intranasal AL 54 AZD# 54 Phase IIa clinical 54 romazarit 54 Pharmacokinetics PK 54 LHRH antagonist 54 Alocrest 54 Nexavar sorafenib 54 ACZ# 54 TELCYTA 54 anti angiogenic 54 ALN TTR# 54 defensin mimetic antibiotic 54 Huntexil 54 Phase 2b trial 54 interferon IFN 54 OMAPRO 54 UsiRNAs 54 milatuzumab 54 Dalbavancin 54 Evoltra ® 54 Junovan TM 54 rindopepimut 54 BRIM2 54 Gemzar ® 54 CYC# 54 CCR5 inhibitor 54 XL# SAR# 54 Factor VIIa 54 MNTX 54 integrase inhibitor 54 Monoclonal antibody 54 Fodosine 54 perifosine 54 Exelixis XL# 54 HDAC inhibitor 54 Aganocide ® 54 tyrosine kinase inhibitors 54 Allovectin 7 R 54 Epothilone D 54 immunotherapeutics 54 E1 INT TM 54 relapsed leukemia 54 Hedgehog signaling pathway 54 AVN# [001] 54 Tesmilifene 54 R#/MEM 54 omega interferon 54 Aptivus ® 54 BioNumerik 54 Apoptone 54 ChronVac C ® 54 humanised monoclonal antibody 54 Aurora Kinase 54 EGFR HER2 54 cytokine refractory 54 panitumumab 54 liposomal 54 CD# monoclonal antibody 54 antisense inhibitors 54 JAK3 54 DR Cysteamine 54 cetuximab Erbitux 54 ALN PCS 54 Prodarsan R 54 VRX# [001] 54 TriRima 54 Ampligen R 54 phase IIb 54 Ambrisentan 54 XL# XL# XL# XL# 54 OvaRex ® MAb 54 castrate resistant prostate cancer 54 mouse xenograft models 54 BiovaxID 54 Zalypsis 54 LymphoStat B TM 54 dimebon latrepirdine 54 MCSP respectively 54 PRX # 54 Vectibix monotherapy 54 Talotrexin 54 thalidomide Thalomid 54 darinaparsin 54 delafloxacin 54 PNP inhibitor 54 outlicensed 54 Phase 2a clinical 54 PBT2 54 phase Ib 54 PROSTVAC TM 54 MOR# 54 Dapagliflozin 54 Akt inhibitor 54 nucleoside analog 54 Voreloxin 54 Anticalins 54 heavily pretreated 54 Solorel 54 CytoFabTM 54 fenretinide 54 IgG1 monoclonal antibody 54 AACR NCI EORTC 54 Ceplene/IL-2 54 NPC 1C 54 teriflunomide 54 elvucitabine 54 IGF 1R 54 omacetaxine 54 Alzhemed TM 54 elesclomol 54 Hsp# Inhibitor 54 Dendreon Provenge 54 disease modifying 54 cetuximab Erbitux R 54 Torisel 54 CEQ# 54 lintuzumab 54 ZFN modified 54 Darusentan 54 DCVax R 54 pseudobulbar affect PBA 54 CRF1 receptor antagonist 54 VentiRx 54 CLORETAZINE TM VNP#M 54 hypoxia activated prodrug 54 CRLX# 54 Cintredekin Besudotox 54 inhibitor RG# 54 MyVax 54 trastuzumab Herceptin ® 54 Golimumab 54 randomized discontinuation trial 54 Capesaris 53 NVA# 53 induces apoptosis 53 anti angiogenic drugs 53 Liposomal 53 DPX Survivac 53 ceftazidime 53 oral bioavailability 53 ThGRF 53 oral proteasome inhibitor 53 BRAF inhibitors 53 Phenoptin 53 XL# XL# XL# 53 AMN# [001] 53 Ophena 53 ADX# 53 rHuPH# 53 EDEMA3 trial 53 Hedgehog pathway 53 fibrotic disease 53 Locteron ® 53 Lupuzor 53 MT#/MEDI-# 53 INCB# [003] 53 TLR9 53 clinical pharmacology studies 53 pegylated liposomal doxorubicin 53 metastatic RCC 53 Theratope 53 siRNAs targeting 53 erlotinib Tarceva 53 Hedgehog Pathway Inhibitor 53 BrachySil 53 tranilast 53 EndoTAGTM 1 53 monoclonal antibody 53 PN# [001] 53 antisense inhibitor 53 GDIR 53 reversible inhibitor 53 mapatumumab 53 ZYBRESTAT fosbretabulin 53 NS#/#A protease 53 MUC1 53 alpha antagonist 53 HepaLife PICM 53 hyaluronidase enzyme 53 resolvin 53 Tasimelteon 53 therapeutic antibody 53 Crizotinib 53 PARP inhibitors 53 StemEx 53 SMT C# 53 antiproliferative effects 53 Ocrelizumab 53 monoclonal 53 GVAX 53 immunotherapeutic agent 53 ganciclovir 53 Corlux 53 BiTE antibodies 53 ChronVac C R 53 CIMZIA TM 53 Fenretinide 53 virus HCV protease inhibitor 53 BRIM3 53 systemic RNAi therapeutic 53 sodium glucose transporter 53 Exherin TM 53 IL# PE#QQR 53 GRN# 53 IRX 2 53 Vidofludimus 53 novel therapeutic antibodies 53 NEUGENE R 53 HE# [002] 53 LBH# 53 intranasal delivery 53 KB# [002] 53 ALD# 53 afatinib 53 Charlesson 53 mRCC 53 renin inhibitors 53 immunotherapies 53 next generation URAT1 53 PI3 kinase inhibitors 53 PI3K inhibitors 53 docetaxel chemotherapy 53 GAMMAGARD 53 PEGylated 53 Darinaparsin 53 Bendavia 53 DAVANAT ® 53 DASISION 53 SinuNase 53 novel histone deacetylase 53 squalamine 53 MBP# [001] 53 AEGR 53 DDP# 53 ibudilast 53 pharmacodynamic properties 53 HuMax TAC 53 Cylene 53 Desmoteplase 53 allosteric modulation 53 PARP inhibitor 53 outlicensing 53 SinuNase ™ 53 panitumumab Vectibix 53 deacetylase inhibitors 53 rFIXFc 53 Degarelix 53 Dacogen decitabine 53 SinuNase TM 53 elacytarabine 53 prodrugs 53 KSP inhibitors 53 myeloproliferative disorders 53 targeted antifolate 53 sorafenib tablets